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ourzone.According to thesedata, and thoseof other
Spanish and European studies [12], a nine-valent
vaccine, including serotypes 1 and 5, could be of
interest in Spain, as it would increase coverage of
children aged < 5 years from 80.2% to 91.7%.
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ABSTRACT
The prevalence of dengue antibodies was deter-
mined in the Attapeu region of South Laos with
225 blood samples collected from mostly febrile
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patients during the rainy season August –
October 2001. An IgM capture ELISA was
positive for one (0.4%) sample, while 177
(79%) samples were positive in an indirect
IgG ELISA. Of the positive IgG samples, 20
(11.3%) were also positive on blood slides for
Plasmodium falciparum. Dengue fever seems to be
widespread in this area, but clinical dengue
diagnosis remains difﬁcult, especially in the ﬁrst
days of illness when physicians have to dis-
criminate between dengue and other febrile
illnesses.
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Dengue is a mosquito-transmitted arboviral
disease, with millions of cases occurring each
year [1]. Dengue virus causes a spectrum of
clinical manifestations such as dengue fever
(DF), a self-limiting ﬂu-like illness with very
low mortality, or dengue hemorrhagic fever
(DHF). Severe cases with signs of circulatory
failure may develop a hypovolaemic shock,
termed dengue shock syndrome (DSS), which
is associated with a case-fatality rate of > 10%
[2]. The dengue virus belongs to the family
Flaviviridae, with infection caused by four
serotypes (DEN-1–DEN-4). Infection in humans
with one of the serotypes (primary infection)
produces life-long immunity against reinfection
with the same serotype, but does not protect
against a different serotype [3]. Secondary infec-
tion with a different serotype following primary
infection is associated with an increased risk of
DHF.
A challenging problem with regard to patient
management is the rapid differential diagnosis
of early symptoms in order to distinguish
dengue from other diseases such as malaria.
Detection of IgM and IgG antibodies is a useful
tool to distinguish between primary and secon-
dary infection. Primary infection is characterised
by the presence of signiﬁcant or rising levels
of IgM antibodies in the period 3–5 days
after onset of infection, and can persist for
3–5 months. Anti-dengue IgG levels are com-
paratively low during primary infection, but
secondary infection often results in the appear-
ance of high levels of IgG before the IgM
reponse. IgG levels rise quickly, peak about
2 weeks after the onset of symptoms, and then
decline slowly over 3–6 months. Anti-dengue
IgM levels are comparatively low during a
secondary infection [3–5]. The objective of the
present study was to examine serum samples
for anti-dengue IgM and IgG antibodies in the
Province of Attapeu in South Laos to provide
basic epidemiological data on the situation of
dengue infections in this rural area.
From August–October 2001, sera from 225
patients, mostly with a history of fever
(n ¼ 129), were collected in the Province of
Attapeu in South Laos. This region is situated
in the south-east part of Lao PDR, close to
the border with Vietnam and Cambodia. The
study was approved by the ethical committee
of the University of Munich, Germany and by
the Ministry of Health, Vientiane, Lao PDR.
The patients were of ethnic Lao Thung or
Lao Loum origin. Inclusion criteria were an
age of > 1 year, fever or history of fever, and
informed consent by the patient or the par-
ents.
Initially, samples from all patients with febrile
symptoms were screened with a Plasmodium
falciparum dipstick test (Paracheck; Orchid, Goa,
India). Following a positive dipstick test, thin
and thick blood smears for malaria were made,
stained with Giemsa by standard procedures,
and later read by experienced technicians in the
hospitals. The blood samples were collected
either in the District Hospital of Xaysettha or
in Attapeu Provincial Hospital, allowed to
coagulate for some hours at 4 C, aliquotted
into tubes, frozen at ) 20 C and later transpor-
ted to Germany (Department of Infectious Dis-
eases and Tropical Medicine, University of
Munich) for further testing. All sera were tested
by two different ELISAs (PanBio, Brisbane,
Australia) for detection of speciﬁc IgM antibod-
ies to dengues–ﬂaviviruses, and for detection of
IgG antibodies to the four dengue serotypes.
Data were stored in a Microsoft Access data-
base, crosschecked, and then transferred into
SPSS v.10 (SPSS Inc, Chicago, IL, USA) for all
statistical analyses.
Table 1 summarises the results obtained. The
IgM capture ELISA was positive for one (0.4%)
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sample from the group aged 10–19 years, while
177 (79%) samples were positive with the
indirect IgG ELISA, which indicates a past or
recent dengue infection. Of the 130 (57.8%)
samples from outpatients in the Province Hos-
pital, 107 were positive in the IgG ELISA. Of
the 95 (42.2%) samples from the District Hos-
pital, one was positive for IgM, and 70 were
positive for IgG. There was no signiﬁcant differ-
ence in IgG prevalence at the province (82.3%) and
district (73.7%) levels. The age distribution was
3–73 years (mean 31 years), with an equivalent
gender distribution (female, 48.2%; male, 51.8%).
There was no signiﬁcant difference in the male:
female ratio between the seropositive (54.7%:
45.3%) and the seronegative (41.9%: 58.1%) sam-
ples. The prevalence of dengue IgG antibodies
within the different age groups increased from
50% in the group (n ¼ 6) aged < 10 years to 92.6%
in the group (n ¼ 25) aged > 50 years. There was a
strong linear association of increasing prevalence
with age (Spearman Correlation 0.233, p < 0.001;
ChiQuadrat 15.4, d.f. ¼ 5, p < 0.009). Unfortu-
nately, no paired samples were available to
distinguish between primary and secondary den-
gue infection. In the IgG-seropositive group, 101
patients reported a recent febrile illness (with a
fever history of 1–7 days), but only 27 patients had
fever of > 37.5 C at presentation (Table 1). Among
all 177 IgG-seropositive patients, 20 were also
positive for P. falciparum, compared to six of
the 48 IgG-seronegative group. In this group,
28 patients reported a history of fever, while
12 patients had a temperature > 37.5 C at
presentation.
This seroprevalence study is, to our knowledge,
the ﬁrst conducted in South Laos, and demon-
strated a seroprevalence of 0.4% for anti-dengue
IgM and of 79% for anti-dengue IgG. High
transmission rates for ﬂaviviruses have been
described in South-east Asia. Therefore serologi-
cal cross-reactivity across the ﬂavivirus group
(e.g., Japanese encephalitis virus) is common at
the IgG level, and the results must be treated with
caution. No previous data on the dengue preval-
ence situation in the Lao PDR are available, but a
similar study from Thailand among children aged
£ 14 years showed that 32% had anti-dengue
antibodies, with 7% of these having a primary
and 93% a secondary infection [5]. Studies in Peru
and Saudi Arabia have shown an overall preval-
ence for dengue IgG of 29.5% and 32%, respect-
ively [6,7].
In the present study, a strong linear association
of increasing antibody prevalence with age was
detected. This may result from a relatively stable
transmission rate over decades. This result is in
line with previous work that also showed an age-
dependent increase of anti-dengue antibodies in
exposed populations [6,8,9]. Other results show
that dengue prevalence depends on time of
exposure, on the risk of getting bitten by an
infected mosquito, and thus strongly on age in
endemic and in epidemic countries. Higher pre-
valence rates are often more common in younger
age groups during and after dengue epidemics
and outbreaks [10].
In endemic areas, misdiagnosis of dengue, Jap-
anese encephalitis or malaria occurs frequently.
Awareness and clinical suspicion for patients
Table 1. Summary of results obtained for 225 serum
samples with the ELISAs for dengue IgM and IgG
antibodies
Dengue
IgG-positive
(n = 177)
Dengue
IgG-negative
(n = 48)
Females (n ¼ 106) 78 (73.6%) 28 (26.4%)
Male (n ¼ 114) 94 (82.4%) 20 (17.6%)
Age (years, n ¼ 224)
< 10 3 (50.0%) 3 (50.0%)
10–19 32 (62.7%) 19 (37.3%)
29–29 47 (81.0%) 11 (10.0%)
30–39 40 (85.1%) 7 (14.9%)
40–49 29 (82.9%) 6 (17.1%)
> 50 25 (92.6%) 2 (7.4%)
Hospital
Province (Attapeu,
n ¼ 130)
107 (82.3%) 23 (17.7%)
District (Xaysettha,
n ¼ 95)
70 (73.7%) 25 (26.3%)
History of fever
(n ¼ 129)
101 (78.3%) 28 (21.7%)
No fever (< 37.5 C) 120 (76.9%) 34 (23.1%)
Fever (> 37.5 C) 27 (69.2%) 12 (30.8%)
P. falciparum-positive 20 (76.9%) 6 (23.1%)
P. falciparum-negative 156 (78.8%) 42 (21.2%)
Dengue IgM
ELISA-positive
1 (100.0%)
Dengue IgM
ELISA-negative
176 (78.6%) 48 (21.4%)
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with similar illness (fever, headache, vomiting,
etc.) are necessary. The present survey demon-
strates that dengue fever may be a problem in the
region of Attapeu Province. Further detailed
serological studies with inclusion of other ﬂavi-
viruses are recommended.
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ABSTRACT
West Nile encephalitis (WNE) presents clinically
as aseptic meningitis, meningoencephalitis,
encephalitis, or acute ﬂaccid paralysis. Non-spe-
ciﬁc laboratory ﬁndings, e.g., leukopenia and
thrombocytopenia, accompany WNE. Lymphope-
nia is marked and prolonged with WNE. Three
patients with WNE were found to have elevated
serum ferritin levels. Severity seemed to be
directly related to serum ferritin levels. Although
preliminary, the results suggested that serum
ferritin levels ‡ 500 ng ⁄mL (normal range 5–
187 ng ⁄mL) occur late with WNE, and not in a
control group of patients with viral meningitis or
encephalitis.
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West Nile encephalitis (WNE) ﬁrst appeared in
the USA in the New York area, and has subse-
quently spread westwards across the USA, with
cases in most states [1–4]. The clinical presenta-
tion may be manifested as aseptic meningitis,
meningoencephalitis, encephalitis, or acute motor
paralysis. The clinical course of WNE presents a
spectrum of illness ranging from mild aseptic
meningitis to fatal encephalitis. WNE is a diag-
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